RedHill Biopharma Ltd. RDHL
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 34.48% | 41.78% | 50.01% | 65.02% | 69.14% |
| Total Depreciation and Amortization | -61.79% | -68.72% | -72.86% | -62.76% | -55.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.03% | 15,832.14% | 138.84% | -88.60% | -88.58% |
| Change in Net Operating Assets | -130.24% | -206.16% | -130.30% | 67.27% | 91.37% |
| Cash from Operations | 36.04% | 52.23% | 63.18% | -302.32% | -15.44% |
| Capital Expenditure | -16.67% | 14.29% | 55.56% | -14.29% | -140.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 3,200.00% | 1,852.38% | 55.56% | -1,700.00% | -220.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 80.29% | 74.21% | 70.28% | 63.33% | 58.90% |
| Issuance of Common Stock | 58.35% | -23.93% | -58.27% | -72.84% | -79.87% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 96.75% | -54.78% |
| Cash from Financing | 62.90% | -23.18% | -58.97% | -64.84% | -80.24% |
| Foreign Exchange rate Adjustments | -104.17% | -75.76% | 0.00% | 306.25% | 196.00% |
| Miscellaneous Cash Flow Adjustments | 59.48% | -40.52% | -- | -- | -- |
| Net Change in Cash | 126.69% | 89.66% | -76.51% | -128.77% | -138.83% |